The latest update is out from Alvotech ( (ALVO) ).

Samsung Bioepis, a biosimilar drug developer under Samsung Group, said Tuesday it has received approval to sell its ...

The FDA’s effort to curb high drug costs by accelerating approvals of cheaper medicines similar to expensive biologics will need other policy reforms to boost access to the biosimilars, drug pricing ...

Mark Cuban drug firm adds cancer biosimilar Vegzelma to its marketplace for hospitals and healthcare providers at discounted prices.

The biosimilar market is set for growth as patents on major biologics expire, creating opportunities for affordable alternatives. Key areas in biosimilar development include regulatory pathways, EU/US ...

Bioeq AG ("Bioeq"), a Swiss biopharmaceutical company, and Zydus Lifesciences Limited ("Zydus"), an innovation-led life-sciences company with an international presence, today announced that its wholly ...

Introduction of AVT05 supported by NHS England tender award in the United KingdomREYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech ...

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma (TM), a ...

The proposed aflibercept biosimilar, which references Regeneron’s Eylea, is a vascular endothelial growth factor receptor Fc ...

Biosimilar uptake varies widely across countries, and the OECD finds no link between stricter promotion regulations and higher adoption. Instead, procurement, pricing policies, and prescriber ...

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.

Samsung Bioepis Co. Ltd. has announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO', ...